Presenting at CMSC 2022, researchers sought to explain the relationship between RLS and quality of life, MS-related disability, and perception of level of disability in patients with MS.
An AAO 2021 presentation reviewed clinical trial data of intravitreal pegcetacoplan, a targeted C3 inhibitor, in controlling lesion growth in patients with geographic atrophy.
Presenting at AAO 2021, researchers examined the efficacy of intravenous infusions of teprotumumab, an IGF-IR inhibitor, in patients with thyroid eye disease with low inflammation.
